Trial Profile
Efficacy of FTY720 in reducing or preventing both focal and diffuse damage of cortical and deep in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Nov 2017
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 22 Nov 2017 New trial record
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis